In short
This article explores the use of Linrodostat Mesilate (BMS-986205), an IDO1 inhibitor, in clinical trials for advanced cancer treatment. The drug is being studied in combination with other immunotherapy agents to assess its safety, tolerability, and potential anti-tumor activity in patients with advanced malignant tumors. This innovative approach aims to provide new treatment options for individuals with difficult-to-treat cancers.
At a glance
- Drug Name
- Linrodostat Mesilate (BMS-986205)
- Drug Class
- IDO1 inhibitor
- Administration
- Oral, film-coated tablet
- Trial Phase
- Phase 1/2
- Target Condition
- Advanced Malignant Tumors
- Combination Therapy
- With nivolumab and ipilimumab
- Primary Objectives
- Safety, tolerability, DLTs, MTD, anti-tumor activity
- Key Endpoints
- Adverse events, ORR, DCR, DOR, PFS
- Eligibility Criteria
- Incurable solid malignancy, measurable disease, ECOG status 0-1
What is LINRODOSTAT MESILATE?
LINRODOSTAT MESILATE, also known as BMS-986205, is an investigational drug being studied for the treatment of advanced cancers. It is classified as an IDO1 inhibitor, which means it targets a specific enzyme in the body that plays a role in cancer growth. This drug is currently being tested in clinical trials to determine its safety and effectiveness in treating various types of advanced malignant tumors.
How Does It Work?
LINRODOSTAT MESILATE works by inhibiting an enzyme called IDO1 (indoleamine 2,3-dioxygenase 1). This enzyme is often overactive in cancer cells and helps them evade the immune system. By blocking IDO1, LINRODOSTAT MESILATE may help the immune system recognize and attack cancer cells more effectively.
What Conditions Does It Treat?
The current clinical trial is focusing on patients with advanced malignant tumors. This term refers to cancers that are either: Metastatic (spread to other parts of the body) Unresectable (cannot be completely removed by surgery) Incurable with standard treatments The trial aims to test LINRODOSTAT MESILATE in various types of solid tumors that have reached an advanced stage.
Current Research
LINRODOSTAT MESILATE is being studied in a Phase 1/2 clinical trial. This trial is testing the drug in combination with other cancer immunotherapy drugs, including: Nivolumab (an anti-PD-1 monoclonal antibody) Relatlimab (an anti-LAG-3 monoclonal antibody) Ipilimumab (an anti-CTLA-4 monoclonal antibody) The main goals of this study are to: Determine the safety and tolerability of these drug combinations Find the best dose for treatment Investigate how effective these combinations are in treating advanced cancers
How Is It Administered?
LINRODOSTAT MESILATE is given as a film-coated tablet that is taken by mouth (oral use). This form of administration is generally more convenient for patients compared to drugs that need to be given by injection or infusion.
Who Is Eligible for the Trial?
The trial has specific criteria for who can participate. Some key eligibility factors include: Having a confirmed diagnosis of an advanced solid tumor that can be measured Having tumor tissue available for biomarker analysis Being in relatively good overall health (ECOG performance status of 0 or 1) Some factors that may exclude a person from participating include: Having uncontrolled cancer that has spread to the brain A history of lung disease called interstitial lung disease or pneumonitis Having other active cancers that require treatment
Safety and Effectiveness
As LINRODOSTAT MESILATE is still in the investigational stage, its full safety profile and effectiveness are not yet known. The current clinical trial is designed to gather this important information. Researchers will be closely monitoring: Side effects and adverse events How well the treatment works in shrinking tumors or stopping cancer growth How long any positive effects last It's important to note that as an experimental treatment, there may be unknown risks and benefits. Patients considering participating in this trial should discuss all potential risks and benefits with their healthcare provider.